Article Sidebar

The percentage of COPD patients divided by age group and Gender
Submitted
April 6, 2023
Published
December 29, 2024
Download
PDF
Statistic
Read Counter : 23 Download : 8

Main Article Content

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disease characterized by persistent airflow limitation and is associated with an increased chronic inflammatory response to certain irritants, gases, or particles. COPD management uses a combination of drugs to treat the disease's symptoms, which varies depending on the patient's condition. The combination of these drugs has the potential to cause drug interactions that result in Drug Related Problems (DRP). A DRP is defined as a change in the effect of a drug due to being given together with other drugs. This study aims to describe the pharmacological therapy given and the potential for drug interactions in COPD therapy at the S.K Lerik Regional General Hospital. This research is descriptive, non-experimental, and observational, using retrospective data. The sample in this study was the medical record data of COPD patients hospitalized at the S.K Lerik Regional General Hospital, with a total sampling technique. The study’s results revealed that the COPD patients’ treatment at the S.K Lerik Hospital mainly uses a combination of corticosteroid therapy (methylprednisolone), bronchodilators (salbutamol), and antibiotics (ceftriaxone). The highest potential for drug interactions was at the mild severity level with the interaction between methylprednisolone and salbutamol, which was given to all patients (12 patients). Due to the high potential for drug interactions of these two drugs, further monitoring is needed in COPD patients to determine the manifestations of these drug interactions in clinical conditions

Keywords

COPD corticosteroid salbutamol antibiotic drug interaction

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

References

  1. Aini, F.N. and Dokhi, M., 2019, Determinan Prevalensi Penyakit Paru Obstruktif Kronis di Indonesia dengan Geographycally Weighted Regression, Prosiding Seminar Nasional Matematika dan Statistika. Samarinda: Universitas Mulawarman, pp. 89–97. Available at: http://jurnal.fmipa.unmul.ac.id/index.php/SNMSA/article/view/531/227 (Accessed: 5 April 2023).
  2. Badan Penelitian dan Pengembangan Kesehatan, 2013, Riset Kesehatan Dasar 2013, Jakarta.
  3. Badan Pusat Statistik, 2020, BPS: Persentase Merokok Pada Penduduk Usia ≤ 18 Tahun, Menurut Jenis Kelamin. Available at: https://www.bps.go.id/indicator/30/1533/1/persentase-merokok-pada-penduduk-usia-18-tahun-menurut-jenis-kelamin.html (Accessed: 5 Maret 2023).
  4. Barnes, P.J., 2013, Theophylline, American Journal of Respiratory and Critical Care Medicine, 188(8), pp. 901–906. Available at: https://doi.org/10.1164/rccm.201302-0388PP.
  5. Bourdet, S. V. and Williams, D.M., 2020, Chronic Obstructive Pulmonary Disease, in J.T. DiPiro, G.C. Yee, M.L. Posey, S.T. Haines, T.D. Nolin, and V.L. Ellingrod (eds) Pharmacotherapy A Pathophysiologic Approach. 11th Edition. McGraw-Hill, pp. 1207–1282.
  6. Cazzola, M., Rogliani, P., Calzetta, L., Hanania, N.A. and Matera, M.G., 2017, Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis, COPD: Journal of Chronic Obstructive Pulmonary Disease, 14(5), pp. 552–563. Available at: https://doi.org/10.1080/15412555.2017.1347918.
  7. Chiu, Y.-C., Chang, W.-P., Tang, G.-J., Lan, T.-Y., Lee, K.-Y. and Su, V.Y.-F, 2022, Chronic obstructive pulmonary disease is associated with a higher risk of functional gastrointestinal disorders, Respiratory Medicine, 197, p. 106833. Available at: https://doi.org/10.1016/j.rmed.2022.106833.
  8. Drugs.com, 2021, Drugs.com Drug Interaction Checker. Available at: https://www.drugs.com/drug_interactions.html
  9. Hanlon, P., Nicholl, B.I., Jani, B.D., McQueenie, R., Lee, D., Gallacher, K.I. and Mair, F.S, 2018, Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional U.K. Biobank study, BMJ Open, 8(1), p. e018404. Available at: https://doi.org/10.1136/bmjopen-2017-018404.
  10. Huckle, A.W., Fairclough, L.C. and Todd, I., 2018, Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics, Respiratory Care, 63(5), pp. 609–619. Available at: https://doi.org/10.4187/respcare.05943.
  11. Johnson, D.B., Merrell, B.J. and Bounds, C.G., 2022, Albuterol, StatPearls Publishing [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482272/ Accessed: 5 April 2023.
  12. Kementerian Kesehatan Republik Indonesia, 2019, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/687/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Paru Obstruktif Kronik. Jakarta
  13. Kusumawardani, N., Rahajeng, E., Mubasyiroh, R. and Suhardi, 2016, Hubungan Antara Keterpajanan Asap Rokok Dan Riwayat Penyakit Paru Obstruktif Kronik (PPOK) di Indonesia, Indonesian Journal of Health Ecology, 15(3), pp. 160–166.
  14. Li, Q., Qu, H.J., Lv, D., Yeh, M.-K., Sun, S., Li, L., and Liao, Y., 2019, Drug-related problems among hospitalized patients with COPD in mainland China, International Journal of Clinical Pharmacy, 41(6), pp. 1507–1515. Available at: https://doi.org/10.1007/s11096-019-00913-4.
  15. Mutmainnah, Restuastuti, T. and Munir, S.M., 2015, Gambaran Kualitas HidupPasien PPOK Stabil di Poli Paru RSUD Arifin Achmad Provinsi Riau dengan Menggunakan Kuesioner SGRQ’, Jurnal Online Mahasiswa Fakultas Kedokteran Universitas Riau, 2(2).
  16. Ntritsos, G., Franek, J., Belbasis, L., Christou, M.A., Markozannes, G., Altman, P., Fogel, R., Sayre, T., Ntzani, E.E. and Evangelou, E., 2018, Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis, International Journal of Chronic Obstructive Pulmonary Disease, Volume 13, pp. 1507–1514. Available at: https://doi.org/10.2147/COPD.S146390.
  17. Ocejo, A. and Correa, R. 2022, Methylprednisolone, StatPearls Publishing [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK544340/ Accessed: 5 April 2023.
  18. Price, D., West, D., Brusselle, G., Gruffydd-Jones, K., Jones, R., Miravitlles, M., Rossi, A., Hutton, C., Ashton, V.L., Stewart, R. and Bichel, K., 2014, Management of COPD in the U.K. primary-care setting: an analysis of real-life prescribing patterns, International Journal of Chronic Obstructive Pulmonary Disease, p. 889. Available at: https://doi.org/10.2147/COPD.S62750.
  19. Reis, A.J., Alves, C., Furtado, S., Ferreira, J., Drummond, M. and Robalo-Cordeiro, C., 2018, COPD exacerbations: management and hospital discharge, Pulmonology, 24(6), pp. 345–350. Available at: https://doi.org/10.1016/j.pulmoe.2018.06.006.
  20. Su, V.Y.-F., Liao, H.-F., Perng, D.-W., Chou, Y.-C., Hsu, C.-C., Chou, C.-L., Chang, Y.-L., Yen, J.-C., Chen, T.-J. and Chou, T.-C., 2018, Proton pump inhibitors use is associated with a lower risk of acute exacerbation and mortality in patients with coexistent COPD and GERD, International Journal of Chronic Obstructive Pulmonary Disease, Volume 13, pp. 2907–2915. Available at: https://doi.org/10.2147/COPD.S157761.
  21. Sundh, J., Åberg, J., Hasselgren, M., Montgomery, S., Ställberg, B., Lisspers, K. and Janson, C., 2017, Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014, European Clinical Respiratory Journal, 4(1), p. 1409060. Available at: https://doi.org/10.1080/20018525.2017.1409060.
  22. Thomsen, M., Nordestgaard, B.G., Vestbo, J. and Lange, P., 2013, Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study, The Lancet Respiratory Medicine, 1(7), pp. 543–550. Available at: https://doi.org/10.1016/S2213-2600(13)70137-1.
  23. Vogelmeier, C.F., Criner, G.J., Martinez, F.J., Anzueto, A., Barnes, P.J., Bourbeau, J., Celli, B.R., Chen, R., Decramer, M., Fabbri, L.M., Frith, P., Halpin, D.M.G., López Varela, M.V., Nishimura, M., Roche, N., Rodriguez-Roisin, R., Sin, D.D., Singh, D., Stockley, R., Vestbo, J., Wedzicha, J.A. and Agustí, A., 2017, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary, American Journal of Respiratory and Critical Care Medicine, 195(5), pp. 557–582. Available at: https://doi.org/10.1164/rccm.201701-0218PP.
  24. Westerik, J.A.M., Metting, E.I., van Boven, J.F.M., Tiersma, W., Kocks, J.W.H. and Schermer, T.R., 2017, Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD, Respiratory Research, 18(1), p. 31. Available at: https://doi.org/10.1186/s12931-017-0512-2.
  25. Whetsel, T.R. and Wietholter, J.P., 2016, Chronic Obstructive Pulmonary Disease, dalam M.A. Chisholm-Burns, T.L. Schwinghammer, B.G. Wells, P.M. Malone, J.M. Kolesar, and J.T. DiPiro (eds) Pharmacotherapy Principles & Practice. 4th Edition. McGraw-Hill Education, pp. 261–273.
  26. World Health Organization, 2023, WHO Fact Details: Chronic obstructive pulmonary disease (COPD). Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(COPD) (Accessed: 20 Maret 2023).
  27. Yawn, B.P., Mintz, M.L. and Doherty, D.E., 2021, GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting, International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, pp. 289–299. Available at: https://doi.org/10.2147/COPD.S222664.